Enabling computational discovery for the brain health research community
The BRAINCommons provides secure access to a collaborative community and state-of-the-art analytic tools that facilitate high quality brain research.
By including data across neurodegenerative diseases, BRAINCommons facilitates research collaboration, data exploration, and reproducibility. The insights it creates will accelerate the development of new therapies for Parkinson’s and similar diseases.
– Todd Sherer, PhD
CEO, The Michael J. Fox Foundation for Parkinson’s Research
Fast-tracking digital health solutions
CVB’s digital health platform EarlySignal (EaSi) aims to improve the well-being of patients by improving how information is collected from wearables and other sensors. Quantifying health and disease with real-time data from wearable devices can enable clinicians to monitor patients’ health, diagnose patients more accurately and tailor treatments accordingly.
Discovering and Validating Biomarkers
Our flagship biomarker discovery platform is a public-private partnership leveraging existing data and stored biosamples to identify biomarkers with the potential to diagnose PTSD and TBI, predict the progression of the conditions, and measure the efficacy of treatments. RAPID-Dx also designs studies to validate biomarkers for use in diagnostic and therapeutic development.
A biomarker is an objectively measured characteristic that may indicate a normal or pathologic disease process, or a response to a therapeutic intervention. By discovering and validating biomarkers, we can fast-track precision diagnostics and tailored therapeutics for brain disorders.
By joining RAPID-Dx, we are affirming our commitment to a new type of radically collaborative science defined by data sharing and coordination of efforts toward our shared goal of finding clinically-useful diagnostics and treatments for these invisible wounds of war. There is no doubt in my mind that coordinated team science will accelerate progress toward diagnosis and treatments. We are thrilled to be working with Cohen Veterans Bioscience.
– Rachel Ramoni, DMD, ScD
Chief Research and Development Officer at the Veterans Health Administration
AMP-IT-UP: Alliance for Modeling Pathological Impacts of Trauma with Unified Practices
Accelerating Drug Discovery Through Rigorous Preclinical Research
Our Preclinical Modeling platform creates alignment across the preclinical research community, offers scientific expertise and program management, and fills funding gaps to support impactful research.
